Allergy & Immunology CE Activities

Harnessing the Full Potential of Frontline Immunotherapy in Advanced NSCLC: Proceedings from a Clinical Olympics℠

1.00 CE Credit(s)

Challenging Cases in Asthma: Improving Quality of Life (3 of 3)

0.25 CE Credit(s)

Challenging Cases in Asthma: Optimizing Biologics in Adults (2 of 3)

0.25 CE Credit(s)

Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes (1 of 3)

0.25 CE Credit(s)

Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria

0.25 CE Credit(s)

Addressing Barriers to EoE Diagnosis and Treatment: The Role of Updated Guidelines and Novel Therapies

1.00 CE Credit(s)

Improving the Treatment of Chronic Spontaneous Urticaria: What Does the Future Hold?

0.50 CE Credit(s)

Overcoming Diagnostic Barriers in Chronic Spontaneous Urticaria

0.25 CE Credit(s)

A Learner Pathway in Moderate-to-Severe AD: Assessing the Role of Interprofessional Collaboration for Improving Patient Care

0.25 CE Credit(s)

Challenging Cases in Atopic Dermatitis: Managing Pediatric Patients and Adults with Multiple Comorbidities

0.25 CE Credit(s)

Challenging Cases in Atopic Dermatitis: Managing Patients with Comorbid Asthma

0.25 CE Credit(s)

RMEI Presentations

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we’ve learned so far

LATEST ALLERGY & IMMUNOLOGY ARTICLES

Latest Allergy & Immunology Articles

Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial October 28, 2021
Asthma affects more than 300 million persons worldwide, and its prevalence is increasing. Severe asthma affects approximately 5 to 10% of persons with asthma. Patients with severe asthma have poor disease control and frequent exacerbations in spite of treatment with high-dose inhaled…
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma October 28, 2021
Currently available biologic therapies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating moderate-to-severe type 2 asthma. However, many patients with type 2 or non–type 2 asthma continue to have symptoms, exacerbations, and reduced lung function. Therefore, new…
Clinical Translation of Basic Science in Asthma October 28, 2021
Basic science has enriched our understanding of the pathophysiology of severe asthma. Clinical translation of these discoveries has resulted in biologic therapies that target key components of asthma-related disease pathways. For example, identification and validation of biomarkers such as elevated…

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.